Author

Hanna Sophie Ritzen

Observed names: H. Ritzen, HANNA RITZÉN, Hanna Ritzen, Hanna Ritzén

Institution: Biovica (Sweden)

Observed institution: Biovica (Sweden)

ORCID: 0009-0007-9995-5825

Observed ORCID: 0009-0007-9995-5825

OpenAlex ID: A5060212814

Recommendations on qPCR/ddPCR Assay Validation by GCC

2022 · Mark Wissel, Martin Poirier, et al. · Bioanalysis · 56

GCC Consolidated Feedback to ICH on the 2019 ICH M10 Bioanalytical Method Validation Draft Guideline

2019 · Corey Nehls, Michael Buonarati, et al. · Bioanalysis · 32

PDF

9th GCC Closed Forum: Capa in Regulated Bioanalysis; Method Robustness, Biosimilars, Preclinical Method Validation, Endogenous Biomarkers, Whole Blood Stability, Regulatory Audit Experiences and Electronic Laboratory Notebooks

2016 · Roger Hayes, Richard LeLacheur, et al. · Bioanalysis · 17

PDF

Recommendations on ELISpot Assay Validation by the GCC

2022 · Rafiq Islam, Jennifer Vance, et al. · Bioanalysis · 16

Recommendations for Classification of Commercial LBA Kits for Biomarkers in Drug Development From the GCC for Bioanalysis

2019 · Rafiq Islam, Sumit Kar, et al. · Bioanalysis · 16

PDF

The 10th GCC Closed Forum: Rejected Data, GCP in Bioanalysis, Extract Stability, BAV, Processed Batch Acceptance, Matrix Stability, Critical Reagents, Eln and Data Integrity and Counteracting Fraud

2017 · Stephanie Cape, Rafiq Islam, et al. · Bioanalysis · 16

PDF

12th GCC Closed Forum: Critical Reagents; Oligonucleotides; CoA; Method Transfer; HRMS; Flow Cytometry; Regulatory Findings; Stability and Immunogenicity

2019 · Chad Briscoe, Nicola Hughes, et al. · Bioanalysis · 14

PDF

Use of liquid biomarker thymidine kinase activity (TKa) to predict outcome and progression in patients with metastatic breast cancer (MBC) in the GEICAM/2014-12 FLIPPER trial.

2024 · Joan Albanell, Amy Williams, et al. · Journal of Clinical Oncology · 4

PDF

Dynamic thymidine kinase activity independently captures treatment-specific biological response and is independently associated with outcomes in endocrine-resistant HR+ /HER2 − metastatic breast cancer: A translational analysis of the GEICAM/2013–02 PEARL trial

2026 · Ángel Guerrero-Zotano, Miguel Gil-Gil, et al. · European Journal of Cancer · 1

PDF

Abstract 971: Thymidine Kinase activity - A liquid biomarker reflecting proliferation rate and treatment efficacy in solid tumors provides unique guidance in oncology trials and drug development

2023 · Mattias K. Bergqvist, Hanna Ritzén, et al. · Cancer Research · 1

Abstract 1899: Thymidine kinase activity as a translational biomarker to support dose optimization in oncology drug development and a tool for monitoring patients.

2026 · Hanna Ritzén, Mattias Bergqvist · Cancer Research

Thymidine kinase activity (TKa) as independent predictor of outcome in metastatic breast cancer (MBC) patients in the GEICAM/2013-02 PEARL trial.

2025 · Angel Guerrero, Miguel J. Gil Gil, et al. · Journal of Clinical Oncology

PDF

Thymidine kinase activity as a prognostic tool in blood samples of primary ovarian cancer patients.

2025 · Stefanos Ioannis Moukas, Sabine Kasimir-Bauer, et al. · Journal of Clinical Oncology

PDF

Abstract 7625: The liquid biomarker thymidine kinase activity reflecting proliferation rate can provide guidance in drug development and address Project Optimus

2024 · Mattias Bergqvist, Hanna Ritzén, et al. · Cancer Research

Po91 a Liquid Biomarker Reflecting Proliferation Rate - Thymidine Kinase Activity - Provides Unique Guidance for Predicting Therapy Efficacy and Monitoring of Advanced Breast Cancer

2023 · Hanna Ritzén, Amy Williams, et al. · The Breast

Comparing the prognostic and predictive utility of serum thymidine kinase 1 and CA 15-3 in patients with hormone receptor positive metastatic breast cancer starting first-line endocrine therapy in SWOG S0226.

2023 · Erin Frances Cobain, William E. Barlow, et al. · Journal of Clinical Oncology

Increased Glucagon, but Reduced GIP Secretion, in Adolescents with Obesity and T2DM

2018 · HJALTI KRISTINSSON, HANNES MANELL, et al. · Diabetes

The initial rise in GIP secretion during OGTT correlates with the initial suppression of glucagon secretion in adolescents with obesity and type 2 diabetes

2018 · Hjalti Kristinsson, Hannes Manell, et al. · Diabetologia

CA-147: Glucagon : Valeurs de Référence & Validation d'un dosage ELISA hautement Spécifique

2016 · M. Kacimi benard, E. Karamihos, et al. · Diabetes & Metabolism

Works count: 19

Citation count: 173

H-index: 7

I10-index: 7